CorMedix Therapeutics Announces Leadership and Board Updates

Core Insights - CorMedix Therapeutics has announced changes in its executive leadership, with CEO Joseph Todisco extending his contract and taking on the role of Chairman of the Board, succeeding Myron Kaplan, who will become the Lead Independent Director [1][2][3] Leadership Changes - Joseph Todisco's extended contract reflects his long-term commitment to CorMedix, and his transition to Chairman is seen as a strategic move to strengthen the company for future success [1][2] - Mike Seckler has been appointed as EVP & Chief Commercial Officer, bringing extensive experience in hematology and oncology, previously serving as CEO of Evome Medical Technologies Inc. [2][3] Company Overview - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including its product DefenCath, which is aimed at preventing catheter-related bloodstream infections in hemodialysis patients [4] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a range of anti-infective products, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV™, BAXDELA, and KIMYRSA [4] Clinical Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric Hemodialysis populations, with plans to develop it as a catheter lock solution for other patient groups [5] - REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [5]